Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 357-366

  Borow, Kenneth M ^a   Nelson, John R ^b   Mason, R Preston ^c  

^a Outcomes and Adherence Program   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndrome; Atherosclerosis; Atherosclerotic plaque; Eicosapentaenoic acid; Endothelial function; Icosapent ethyl; Inflammation; Thrombosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; AUTACOID; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; LIPID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FOAM CELL; HIGH RISK PATIENT; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION; VASODILATATION; ANIMAL; ARTERY; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; ATHEROSCLEROSIS; BIOMARKERS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FIBRINOLYTIC AGENTS; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; LIPIDS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939559523     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.035     Document Type: Review

References (115)

1. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 1999, 282(8):790-795.
2. Thygesen L.C., Andersen G.S., Andersen H. A philosophical analysis of the Hill criteria. J. Epidemiol. Community Health 2005, 59(6):512-516.
3. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014, 384(9943):626-635.
4. Rosenson R.S., Davidson M.H., Hirsh B.J., Kathiresan S., Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 2014, 64(23):2525-2540.
5. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92(3):657-671.
6. Fruchart J.C., Davignon J., Hermans M.P., Al-Rubeaan K., Amarenco P., Assmann G., et al. Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol. 2014, 13(1):26.
7. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
8. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of Cardiology/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2014, 63(25):2889-2934.
9. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372(25):2387-2397.
10. McPherson R., Hegele R.A. Ezetimibe: rescued by randomization (clinical and Mendelian). Arterioscler. Thromb. Vasc. Biol. 2015, 35(3):e13-e15.
11. Sabatine M.S., Giugliano R.P., Wiviott S.D., Raal F.J., Blom D.J., Robinson J., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372(16):1500-1509.
12. Robinson J.G., Farnier M., Krempf M., Bergeron J., Luc G., Averna M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372(16):1489-1499.
13. Jarcho J.A., Keaney J.F. Proof that lower is better - LDL cholesterol and IMPROVE-IT. N. Engl. J. Med. 2015, 372(25):2448-2450.
14. Jump D.B., Depner C.M., Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J. Lipid Res. 2012, 53(12):2525-2545.
15. Larsson S.C., Kumlin M., Ingelman-Sundberg M., Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr. 2004, 79(6):935-945.
16. Arterburn L.M., Hall E.B., Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 2006, 83(6 Suppl. l):1467S-1476S.
17. Bays H.E., Ballantyne C.M., Braeckman R.A., Stirtan W.G., Soni P.N. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am. J. Cardiovasc Drugs 2013, 13(1):37-46.
18. Mason R.P., Jacob R.F. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim. Biophys. Acta 2015, 1848(2):502-509.
19. Brinton E.A., Ballantyne C.M., Bays H.E., Kastelein J.J., Braeckman R.A., Soni P.N. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013, 12(1):100.
20. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011, 58(20):2047-2067.
21. Blaha M.J., Martin S.S. How do statins work?: changing paradigms with implications for statin allocation. J. Am. Coll. Cardiol. 2013, 62(25):2392-2394.
22. Montezano A.C., Touyz R.M. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin. Pharmacol. Toxicol. 2012, 110(1):87-94.
23. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell 2001, 104(4):503-516.
24. Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G., Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014, 371(1):32-41.
25. TG and HDL Working Group of the Exome Sequencing Project NHLaBI Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014, 371(1):22-31.
26. Khetarpal S.A., Rader D.J. Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. Arterioscler. Thromb. Vasc. Biol. 2015, 35(2):e3-e9.
27. Libby P. Triglycerides on the rise: should we swap seats on the seesaw?. Eur. Heart J. 2015, 36(13):774-776.
28. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99(22):2858-2860.
29. Fukushima H., Sugiyama S., Honda O., Koide S., Nakamura S., Sakamoto T., et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J. Am. Coll. Cardiol. 2004, 43(12):2219-2224.
30. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61(4):427-436.
31. Wang L., Gill R., Pedersen T.L., Higgins L.J., Newman J.W., Rutledge J.C. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 2009, 50(2):204-213.
32. Eiselein L., Wilson D.W., Lame M.W., Rutledge J.C. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2007, 292(6):H2745-H2753.
33. Tomono S., Kawazu S., Kato N., Ono T., Ishii C., Ito Y., et al. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J. Atheroscler. Thromb. 1994, 1(2):98-102.
34. Rapp J.H., Lespine A., Hamilton R.L., Colyvas N., Chaumeton A.H., Tweedie-Hardman J., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 1994, 14(11):1767-1774.
35. Doi H., Kugiyama K., Oka H., Sugiyama S., Ogata N., Koide S.I., et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000, 102(6):670-676.
36. Kjalke M., Silveira A., Hamsten A., Hedner U., Ezban M. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler. Thromb. Vasc. Biol. 2000, 20(7):1835-1841.
37. Moyer M.P., Tracy R.P., Tracy P.B., van't Veer C., Sparks C.E., Mann K.G. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol. 1998, 18(3):458-465.
38. Mack W.J., Krauss R.M., Hodis H.N. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler. Thromb. Vasc. Biol. 1996, 16(5):697-704.
39. Krauss R.M., Lindgren F.T., Williams P.T., Kelsey S.F., Brensike J., Vranizan K., et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987, 2(8550):62-66.
40. Tousoulis D., Kampoli A.M., Tentolouris C., Papageorgiou N., Stefanadis C. The role of nitric oxide on endothelial function. Curr. Vasc. Pharmacol. 2012, 10(1):4-18.
41. Mason R.P., Jacob R.F., Corbalan J.J., Malinski T. Combination eicosapentaenoic acid and statin treatment reversed endothelial dysfunction in HUVECs exposed to oxidized LDL. J. Clin. Lipidol. 2014, 8(3):342-343. [abstract 160].
42. Lee C.H., Lee S.D., Ou H.C., Lai S.C., Cheng Y.J. Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK/eNOS pathway. Int. J. Mol. Sci. 2014, 15(6):10334-10349.
43. Ishida T., Naoe S., Nakakuki M., Kawano H., Imada K. Eicosapentaenoic acid prevents saturated fatty acid-induced vascular endothelial dysfunction: involvement of long-chain acyl-CoA synthetase. J. Atheroscler. Thromb. 2015, (Epub ahead of print).
44. Mason R.P., Jacob R., Beauregard G., Rowe J. Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors. J. Clin. Lipidol. 2011, 5(3):201. [abstract].
45. Chiu S.C., Chiang E.P., Tsai S.Y., Wang F.Y., Pai M.H., Syu J.N., et al. Eicosapentaenoic acid induces neovasculogenesis in human endothelial progenitor cells by modulating c-kit protein and PI3-K/Akt/eNOS signaling pathways. J. Nutr. Biochem. 2014, 25(9):934-945.
46. Sasaki J., Miwa T., Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr. J. 2012, 59(4):297-304.
47. Toyama K., Nishioka T., Isshiki A., Ando T., Inoue Y., Kirimura M., et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014, 28(1):53-59.
48. Yamakawa K., Shimabukuro M., Higa N., Asahi T., Ohba K., Arasaki O., et al. Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol. Res. Pract. 2012, 2012:754181.
49. Takaki A., Umemoto S., Ono K., Seki K., Ryoke T., Fujii A., et al. Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study. J. Atheroscler. Thromb. 2011, 18(10):857-866.
50. Zheng X.Y., Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res. 2007, 48(8):1673-1680.
51. Ballantyne C.M., Bays H.E., Braeckman R.A., Philip S., Stirtan W.G., Doyle R.T., et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Circulation 2014, 130(Suppl. 2):A16803. [abstract].
52. Satoh N., Shimatsu A., Kotani K., Sakane N., Yamada K., Suganami T., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30(1):144-146.
53. Ley K., Miller Y.I., Hedrick C.C. Monocyte and macrophage dynamics during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2011, 31(7):1506-1516.
54. Ghattas A., Griffiths H.R., Devitt A., Lip G.Y., Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now?. J. Am. Coll. Cardiol. 2013, 62(17):1541-1551.
55. Nomura S., Shouzu A., Omoto S., Inami N., Ueba T., Urase F., et al. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J. Atheroscler. Thromb. 2009, 16(2):83-90.
56. Grenon S.M., Aguado-Zuniga J., Hatton J.P., Owens C.D., Conte M.S., Hughes-Fulford M. Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion. J. Surg. Res. 2012, 177(1):e35-e43.
57. Yamada H., Yoshida M., Nakano Y., Suganami T., Satoh N., Mita T., et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler. Thromb. Vasc. Biol. 2008, 28(12):2173-2179.
58. Thies F., Garry J.M., Yaqoob P., Rerkasem K., Williams J., Shearman C.P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361(9356):477-485.
59. Nishio R., Shinke T., Otake H., Nakagawa M., Nagoshi R., Inoue T., et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis 2014, 234(1):114-119.
60. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 2011, 13(6):474-483.
61. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
62. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 2009, 30(23):2838-2844.
63. Adkins Y., Kelley D.S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J. Nutr. Biochem. 2010, 21(9):781-792.
64. Spite M., Claria J., Serhan C.N. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014, 19(1):21-36.
65. Hasturk H., Abdallah R., Kantarci A., Nguyen D., Giordano N., Hamilton J., et al. Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2015, 35(5):1123-1133.
66. Vascepa [package Insert] 2015, Amarin Pharma Inc., Bedminster, NJ.
67. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J. Biol. Chem. 2010, 285(43):32720-32733.
68. Spector A.A., Kim H.Y. Cytochrome P epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochim. Biophys. Acta 2015, 1851(4):356-365.
69. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285(5431):1276-1279.
70. Bays H.E., Ballantyne C.M., Braeckman R.A., Stirtan W.G., Doyle R.T., Philip S., et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 2015, 13(6):239-247.
71. Doi M., Nosaka K., Miyoshi T., Iwamoto M., Kajiya M., Okawa K., et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int. J. Cardiol. 2014, 176:577-582.
72. Dangardt F., Osika W., Chen Y., Nilsson U., Gan L.M., Gronowitz E., et al. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 2010, 212(2):580-585.
73. Satoh-Asahara N., Shimatsu A., Sasaki Y., Nakaoka H., Himeno A., Tochiya M., et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012, 35(12):2631-2639.
74. Cawood A.L., Ding R., Napper F.L., Young R.H., Williams J.A., Ward M.J., et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010, 212(1):252-259.
75. Nozue T., Yamamoto S., Tohyama S., Fukui K., Umezawa S., Onishi Y., et al. Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am. J. Cardiol. 2013, 111(1):6-11.
76. Serikawa T., Miura S., Okabe M., Hongo H., Tokutome M., Yoshikawa T., et al. Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients. J. Cardiol. 2014, 63(1):35-40.
77. Wakabayashi Y., Funayama H., Ugata Y., Taniguchi Y., Hoshino H., Momomura S., et al. Eicosapentaenoic acid to arachidonic acid ratio is associated with the presence of thin-cap fibroatheroma determined by optical coherence tomography. Eur. Heart J. 2014, 35(Suppl. 1):610. [abstract P3412].
78. Braeckman R.A., Manku M.S., Bays H.E., Stirtan W.G., Soni P.N. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostagl. Leukot. Essent. Fat. Acids 2013, 89(4):195-201.
79. Domei T., Amemiya K., Enomoto S., Ichihashi K., Yokoi H., Iwabuchi M., et al. Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy. Eur. Heart J. 2013, 34(Suppl. 1):137. [abstract P689].
80. Tanaka N., Ishida T., Nagao M., Mori T., Monguchi T., Sadaki M., et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 2014, 237(2):577-583.
81. Yamano T., Kubo T., Shiono Y., Shimamura K., Orii M., Tanimoto T., et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J. Atheroscler. Thromb. 2015, 22(1):52-61.
82. Uehara H., Miyagi N., Shimajiri M., Nago C. The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis. Eur. Heart J. 2013, 34(Suppl. 1):1011. [abstract P5495].
83. Niki T., Wakatsuki T., Bando M., Ogasawara K., Bando S., Matsuura T., et al. Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems. Circulation 2012, 126(21Suppl. l):14434. [abstract 14434].
84. Wakita Y., Wakida Y., Itou T., Mizuno R. High-purity-eicosapentaenoic-acid in addition to a strong statin makes regression of coronary plaque in patients with angina-pectoris and impaired glucose tolerance. Circ. J. 2013, 77(Suppl. 1). [abstract], I-2678.
85. Shintani Y., Kawasaki T. The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography. J. Am. Coll. Cardiol. 2012, 59(13):E1731. [abstract].
86. Mita T., Watada H., Ogihara T., Nomiyama T., Ogawa O., Kinoshita J., et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007, 191(1):162-167.
87. Katoh A., Ikeda H. Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia. Ther. Res. 2011, 32(6):863-868. [in Japanese].
88. Maeda K. Effect of highly purified eicosapentaenoic acid (EPA) for patients with multiple artery atherosclerotic risk factors and clinical usefulness of the ratio of serum EPA to arachidonic acid (AA) as the indicator of therapy effect of atherosclerosis. Ther. Res. 2014, 35(2):177-182. [in Japanese].
89. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. U. S. A. 1979, 76(2):944-948.
90. Bays H.E., Ballantyne C.M., Kastelein J.J., Isaacsohn J.L., Braeckman R.A., Soni P.N. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial). Am. J. Cardiol. 2011, 108(5):682-690.
91. Ballantyne C.M., Bays H.E., Kastelein J.J., Stein E., Isaacsohn J.L., Braeckman R.A., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 2012, 110(7):984-992.
92. Ballantyne C.M., Bays H.E., Braeckman R.A., Stirtan W.G., Doyle R.T., Juliano R., et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies. J. Clin. Lipidol. 2014, 8(3):313-314. [abstract 122].
93. Bays H.E., Tighe A.P., Sadovsky R., Davidson M.H. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc Ther. 2008, 6(3):391-409.
94. Saito Y., Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Ishikawa Y., et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2008, 200(1):135-140.
95. Matsuzaki M., Yokoyama M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ. J. 2009, 73(7):1283-1290.
96. Tanaka K., Ishikawa Y., Yokoyama M., Origasa H., Matsuzaki M., Saito Y., et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008, 39(7):2052-2058.
97. Oikawa S., Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2009, 206(2):535-539.
98. Itakura H., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., et al. Relationships between plasma fatty acid composition and coronary artery disease. J. Atheroscler. Thromb. 2011, 18(2):99-107.
99. Sasaki J., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA lipid intervention study (JELIS). J. Atheroscler. Thromb. 2012, 19(2):194-204.
100. Nasu M., Seino K., Tamura Y., Suzuki M., Iwabuchi Y., Maeda N., et al. Eicosapentaenoic acid restrains the development of the cardiovascular events independent of triglyceride and C-reactive protein reduction in Japanese hemodialysis patients. Eur. Heart J. 2013, 34(Suppl. 1):271. [abstract P1428].
101. Inoue T., Okano K., Tsuruta Y., Tsuruta Y., Tsuchiya K., Akiba T., et al. Eicosapentaenoic acid (EPA) is an independent predictor of all-cause mortality in hemodialysis patients. Nephrol. Dial. Transpl. 2013, 28(Suppl. 1):i257. [abstract SP578].
102. Inagaki H., Yokota N., Sato Y., Chiyotanda S., Fukami K., Fujimoto S. EPA ethyl ester increases EPA/AA ratio and decreases carboxylmethyl lysine in dialysis patients. Nephrol. Dial. Transpl. 2014, 29(Suppl. 3):iii240. [abstract SP504].
103. Ando M., Sanaka T., Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J. Am. Soc. Nephrol. 1999, 10(10):2177-2184.
104. GISSI Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177):447-455.
105. GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1223-1230.
106. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363(21):2015-2026.
107. ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 2012, 367(4):309-318.
108. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122(21):2152-2159.
109. Mozaffarian D., Marchioli R., Macchia A., Silletta M.G., Ferrazzi P., Gardner T.J., et al. Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of Post-operative atrial fibrillation (OPERA) randomized trial. JAMA 2012, 308(19):2001-2011.
110. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368:1800-1808. The Risk and Prevention Study Collaborative Group.
111. Lovaza [package Insert] 2013, GlaxoSmithKline, Research Triangle Park, NC.
112. Epanova [package Insert] 2014, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
113. Omtryg [package Insert] 2014, Trygg Pharma, Inc., Arlington, VA.
114. Joshi P.H., Martin S.S., Blumenthal R.S. The remnants of residual risk. J. Am. Coll. Cardiol. 2015, 65(21):2276-2278.
115. Schmier J.K., Hulme-Lowe C., Nelson J.R., Chowdhury S., Everett P.B., Philip S. A novel cost effectiveness model of eicosapentaenoic acid (EPA) for secondary prevention in the United States. Circ. Cardiovasc Qual. Outcomes 2015, 8:A243. [abstract 243].